Cost-effectiveness of implementing guidelines for the treatment of glucocorticoid-induced osteoporosis in Japan

ConclusionsThe cost-effectiveness of preventive alendronate therapy for postmenopausal women with osteopenia or osteoporosis using GC is sensitive to age, BMD, GC dose, and the presence of previous fracture. Our analysis suggested that the treatment indication for postmenopausal women with osteopenia or osteoporosis using GC in the current Japanese clinical guidelines is likely to be cost-effective except for the limited patients who are at low risk for fracture.
Source: Osteoporosis International - Category: Orthopaedics Source Type: research